Aspirin Bioactivity for Prevention of Cardiovascular Injury in COVID-19

Frontiers in Cardiovascular Medicine

Armando A. Durant-Archibold²  Temistocles Diaz²  Barry H. Trachtenberg³  Samuel J. K. Abraham⁵  Rao KosagiSharaf⁷ 

[1] Centre for Advancing Clinical Research (CACR), Yamanashi University, Chuo, Japan;Biomedicine Research Unit, Center for Biodiversity and Drug Discovery, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT Asociation of Public Interest), Panama City, Panama;Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, United States;;Department of Surgery &Edogawa Evolutionary Laboratory of Science (EELS), Edogawa Hospital, Tokyo, Japan;Internal Medicine-Interventional Cardiology, Department of Cardiology, Punta Pacifica Hospital, Affiliate of John Hopkins Medicine International, Panama City, Panama;The Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India;

关键词: molecular mechanisms;    aspirin;    SARS-CoV-2;    COVID-19;    prevention of cardiovascular disease;   

DOI  :  10.3389/fcvm.2020.562708

来源: DOAJ

【 授权许可】

Unknown